111, Inc., a leading integrated online and offline healthcare platform, announced  that it will establish an integrated online and offline healthcare retail channel with HEC Group. The channel will be used to expand the offering of HEC's products and resources to more patients, both online and offline.

The signing ceremony was conducted by Yushuai Zhang, Chairman of Guangdong HEC Technology Holding Co., Ltd., Yangui Chen, Executive Director of Yichang HEC, Dr. Gang Yu, Co-Founder and Executive Chairman of 111, Haihui Wang, Chief Operating Officer of 111, and Yang Chen, Chief Financial Officer of 111. HEC is the parent company of Yichang HEC Changjiang Pharmaceutical Co., Ltd.

Under the partnership, in addition to focusing on cardio cerebrovascular and endocrine diseases, 111 will support HEC in designing solutions for direct sourcing, distribution management, and e-commerce, and both parties will also collaborate on brand visibility and patient education.

Haihui Wang, Chief Operating Officer of 111, commented: "As the healthcare needs of China continue to grow, 111 is empowering pharmaceutical companies to bring innovative products to market.  We are constantly enriching the product verticals on our platforms to serve the needs of patients. We have been very impressed by HEC's manufacturing quality management system, the range of its products offerings, and innovative products."

Yangui Chen, Executive Director of Yichang HEC, commented: "Yichang HEC is an advocate of diagnosis and treatment based on advanced scientific method. "KeWei" Oseltamivir Phosphate Granules is a top influenza drug internationally and domestically, and the HEC Group has global exclusive rights to produce it. With the development of clinical and consumer awareness about influenza, an increasing number of people have heard of Oseltamivir, have used this drug, and are gradually learning about HEC. We are planning to use a range of market distribution channels for our innovative products in the future. The Internet makes it possible to provide precise information to patients, and the new distribution channel outside hospitals that we will develop with 111 will be an important strategic departure for us."

China's healthcare reforms are bringing unprecedented changes to the traditional pharmaceutical distribution market. Pharmaceutical manufacturers are under pressure to switch their focus to new drug development. At the same time, China has allowed conditional online prescription drug sales, and the Internet Drug Sale Supervision Measures are under review. 111 is ideally positioned in the market as the Chinese government is liberalizing drug distribution beyond hospitals.